Generate Biomedicines, Inc. (GENB) Stock Forecast
Data as of May 10, 2026Financial Services · Current price $13.57 (-0.37%)
Consensus Target
$25.00
Upside
+84.2%
Analysts
1
Rating
Buy(2.00)
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
No analyst price targets available.
GENB vs Sector & Market
| Metric | GENB | Financial Services Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.51 | 2.41 |
| Analyst Count | 1 | 8 | 19 |
| Target Upside | +84.2% | +62.3% | +16.4% |
| P/E Ratio | -3.07 | -4.65 | 27.60 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $20M | $26M | $33M | 5 |
| 2027-12-31 | $4M | $21M | $35M | 5 |
| 2028-12-31 | $47M | $92M | $135M | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-2.34 | $-2.01 | $-1.66 | 3 |
| 2027-12-31 | $-2.32 | $-2.02 | $-1.73 | 3 |
| 2028-12-31 | $-2.50 | $-2.21 | $-1.92 | 2 |
Frequently Asked Questions
What is the analyst consensus for GENB?
The consensus among 1 analysts covering Generate Biomedicines, Inc. (GENB) is Buy with an average price target of $25.00.
How many analysts cover GENB?
1 analysts have issued ratings for Generate Biomedicines, Inc. in the past 12 months.
Is GENB a buy or sell right now?
Based on 1 analyst ratings, GENB has a consensus rating of Buy (2.00/5) with a +84.2% upside to the consensus target of $25.00.
What are the earnings estimates for GENB?
Analysts estimate GENB will report EPS of $-2.01 for the period ending 2026-12-31, with revenue estimated at $26M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.